These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy. Hu M; Zhang J; Yu Y; Tu K; Yang T; Wang Y; Hu Q; Kong L; Zhang Z Small; 2020 Dec; 16(50):e2004905. PubMed ID: 33206460 [TBL] [Abstract][Full Text] [Related]
9. Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. Song C; Phuengkham H; Kim YS; Dinh VV; Lee I; Shin IW; Shin HS; Jin SM; Um SH; Lee H; Hong KS; Jin SM; Lee E; Kang TH; Park YM; Lim YT Nat Commun; 2019 Aug; 10(1):3745. PubMed ID: 31431623 [TBL] [Abstract][Full Text] [Related]
10. Sponge-like nano-system suppresses tumor recurrence and metastasis by restraining myeloid-derived suppressor cells-mediated immunosuppression and formation of pre-metastatic niche. Xia C; Bai W; Deng T; Li T; Zhang L; Lu Z; Zhang Z; Li M; He Q Acta Biomater; 2023 Mar; 158():708-724. PubMed ID: 36638937 [TBL] [Abstract][Full Text] [Related]
11. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843 [TBL] [Abstract][Full Text] [Related]
13. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Santiago-Sánchez GS; Hodge JW; Fabian KP Front Immunol; 2022; 13():993624. PubMed ID: 36159809 [TBL] [Abstract][Full Text] [Related]
14. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V Front Immunol; 2018; 9():398. PubMed ID: 29552012 [TBL] [Abstract][Full Text] [Related]
15. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related]
16. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605 [TBL] [Abstract][Full Text] [Related]
17. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. Buoncervello M; Gabriele L; Toschi E Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464 [TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice. Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369 [TBL] [Abstract][Full Text] [Related]
19. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678 [TBL] [Abstract][Full Text] [Related]
20. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer. Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]